Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an update.
Kontafarma China Holdings has called its annual general meeting for 5 June 2026 in Hong Kong, where shareholders will be asked to receive and adopt the audited financial statements for the year ended 31 December 2025. The agenda also includes re-election of four directors, authorization for the board to set directors’ fees for 2026 and re-appointment of BDO Limited as independent auditor.
Investors will additionally vote on a general mandate allowing the board to issue, allot or deal in up to 20% of the company’s issued share capital, excluding treasury shares, outside of specified exceptions such as rights issues and employee share schemes. The proposed mandate, a common capital-management tool in Hong Kong, would give the board greater flexibility to raise equity or conduct corporate actions, potentially affecting shareholder dilution and the company’s future financing options.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates as a diversified company under the oversight of a board comprising executive, non-executive and independent non-executive directors. The group is subject to the corporate governance and disclosure requirements of the Hong Kong capital markets, with its financial reporting audited by BDO Limited.
Average Trading Volume: 1,461,857
Technical Sentiment Signal: Sell
Current Market Cap: HK$167.4M
For detailed information about 1312 stock, go to TipRanks’ Stock Analysis page.